Savient Appoints Chief Financial Officer and Treasurer

While at Bone Care, Mr. Hayden was a member of the seniormanagement team that transitioned the Company to profitability, raisedin excess of $100 million in a secondary public offering, increasedits research coverage and grew the market capitalization fromapproximately $150 million to in excess of $700 million. Prior tojoining Bone Care, Mr. Hayden served as Vice President, ChiefFinancial Officer and Treasurer of Cell Pathways, Inc. Mr. Hayden hasalso held financial management positions at Hoffmann-La Roche, Inc.Mr. Hayden holds a BBA from Loyola University.

"Brian's extensive experience in the industry, including financialmanagement, planning and budgeting, SEC reporting, investor relationsand Sarbanes Oxley compliance at both small and large pharmaceuticaland biotechnology companies, will be of significant value to Savient,"said Christopher Clement, President and Chief Executive Officer. "Wewelcome Brian to our senior management team and believe that hisinsight and participation on financial management and control issueswill be instrumental to the success of our organization as we advanceour strategy of completing our phase 3 clinical trials with Puricasefor treatment-failure gout and move forward into our productcommercialization and launch efforts."

In order to ensure a smooth and orderly transition, Gina Gutzeit,who has been serving as Interim Chief Financial Officer, will continuewith the Company in a consulting role in order to accomplish thistransition over the next few weeks.

ABOUT SAVIENT

Based in East Brunswick, New Jersey, Savient Pharmaceuticals,Inc., is a specialty pharmaceuticals company and is engaged indeveloping, manufacturing and marketing pharmaceutical products thataddress unmet medical needs in both niche and broader markets. TheCompany's lead product development candidate, Puricase(R)(PEG-uricase), for the treatment of refractory gout has reportedpositive Phase 1 and 2 clinical data. Savient's experienced managementteam is committed to advancing its pipeline and expanding its productportfolio by in-licensing late stage compounds and exploringco-promotion and co-development opportunities that fit the Company'sexpertise in specialty pharmaceuticals and initial focus inrheumatology. Savient markets its product Oxandrin(R) (oxandrolone,USP) in the United States. The Company's subsidiary, RosemontPharmaceuticals Ltd., develops, manufactures, and markets through itsown sales force oral liquid formulations of prescription products forthe UK pharmaceutical market. Rosemont's product portfolio includesover 100 liquid formulations primarily targeting the geriatricpopulation. Puricase is a registered trademark of Mountain ViewPharmaceuticals, Inc. Further information on the Company can beaccessed by visiting www.savientpharma.com.